连环推 ×6许多药物通过与体内特定靶点结合并阻断或改变其功能来发挥作用。药物开发过程中的重要第一步是设计一个能紧密结合靶点的分子。传统上，这需要每个靶点花费数周或数月的专家工作，从众多候选物中筛选出少数有效的。我们想测试 Claude 是否能从零开始成功设计新型蛋白质绑定器（也叫de novo design）。利用人类专家编写的蛋白质设计提示词，Claude 自主地为 15 个靶点中的 14 个设计了蛋白质绑定器。随后我们与 Adaptyv Bio 和 Twist Bioscience 合作，他们独立地构建并测试了 Claude 设计的蛋白质。
设计绑定器比设计药物更简单，但它是个有用的替代指标。目前业界的典型成功率在 10% 到 15% 之间。而 Claude 设计的绑定器中有 22% 到 35% 成功结合，具体取决于设置方式。其中一些最强设计的结合力是已发表最佳新型绑定器的数倍。
重要的是，蛋白质绑定器并不是药物。设计高亲和力绑定器只是开发类药物分子过程中的第一步。即使设计药物本身，也只是确立药物安全有效所需的众多阶段之一。不过这为我们建立了坚实的基础。我们正在此基础上建设，教会 Claude 能够为每一类主要药物分子（从抗体到小分子）端到端地运行整个开发流程。
我们最优先的任务之一是为科学家推出访问计划，让他们能使用我们最强大的模型。我们预计很快会分享更多信息。Opus 5 仍然是我们用于生命科学研究的最强大模型。
想看 Claude 怎么做这个实验以及完整结果，可以查看我们的博客：
anthrpoic.com/research/Claud…
我们还发布了一份技术报告：
www-cdn.anthropic.com/30bf50…
以及在这儿开源我们的提示词和数据：
huggingface.co/datasets/Anth…
查看英文原文
We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets.
We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
Designing a binder is an easier process than designing a drug, but it’s a useful proxy. The typical success rate in the field today is between 10% and 15%.
Between 22% and 35% of Claude's designs bound successfully, depending on the setup. Some of its strongest designs bound several times more tightly than the best published de novo binder.
Importantly, protein binders are not drugs. Designing a high-affinity binder is just the first step in the process of developing a drug-like molecule. Even designing a drug itself is just one phase out of the many required to establish that a drug is safe and effective before making it available to people.
However, this establishes a strong foundation to work from, and we are building on it by teaching Claude to run the entire development process end-to-end for every major type of drug molecule—from antibodies to small molecules.
One of our highest priorities remains launching an access program for scientists to use our most capable models. We expect to share more on this soon. Opus 5 remains our most capable model available for life science research.
For more on how Claude ran this experiment and the full results, see our blog:
anthropic.com/research/Claud…
We're also publishing a technical report:
www-cdn.anthropic.com/30bf50…
And open-sourcing our prompts and data here:
huggingface.co/datasets/Anth…
